Logo

Protagonist Collaborates with Janssen to Advance PN-235 (JNJ-77242113) in P-II Clinical Studies for Multiple Indications

Share this

Protagonist Collaborates with Janssen to Advance PN-235 (JNJ-77242113) in P-II Clinical Studies for Multiple Indications

Shots:

  • Protagonist to receive $25M milestone for the initiation of 1st P-II study of PN-235 in psoriasis, $10M milestone for 2nd indication-based P-II study & ~$900M in development milestone
  • Under May 30, 2017 agreement, the Protagonist receives an up front & milestone along with royalties while on Oct 26, 2021, the Protagonist receives a $7.5M milestone. Janssen will be responsible for clinical studies including P-II studies & will be financially responsible for studies
  • The P-II clinical studies of PN-235 for IBD are expected to start in late 2022 & development of PN-232 will discontinue based on its superior potency, PK & PD profile. PN-943 is being evaluated in the P-II study for active UC

Ref: PR Newswire | Image: Protagonist 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions